<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703820</url>
  </required_header>
  <id_info>
    <org_study_id>AML08</org_study_id>
    <secondary_id>R01CA138744</secondary_id>
    <secondary_id>R01CA115422</secondary_id>
    <secondary_id>R01CA132946</secondary_id>
    <secondary_id>NCI-2011-03659</secondary_id>
    <nct_id>NCT00703820</nct_id>
  </id_info>
  <brief_title>Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility and efficacy of a novel form of&#xD;
      therapy-haploidentical NK cell transplantation-in patients with standard-risk AML. In&#xD;
      addition, we will investigate the efficacy of clofarabine + cytarabine (Clo/AraC) in newly&#xD;
      diagnosed patients with AML and attempt to optimize outcome through the use of MRD-adapted&#xD;
      therapy and further improvements in supportive care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this protocol is to improve the cure rate of acute myeloid leukemia&#xD;
      (AML).&#xD;
&#xD;
      We will compare the immunologic complete response rate after one course of therapy in&#xD;
      patients who receive cytarabine + daunorubicin + etoposide (ADE) with that in patients who&#xD;
      receive clofarabine + cytarabine (Clo/AraC)&#xD;
&#xD;
      Secondary objectives include&#xD;
&#xD;
        -  To estimate the event-free survival (EFS) of standard risk (SR) patients who receive&#xD;
           chemotherapy alone and the EFS of SR patients who receive chemotherapy followed by&#xD;
           natural killer (NK) cell transplantation.&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
        -  To genotype natural killer (NK) cell receptors and measure their expressions at&#xD;
           diagnosis and after induction therapy, and to explore the associations of these features&#xD;
           with treatment outcome&#xD;
&#xD;
        -  To assess the prognostic value of levels of minimal residual disease in peripheral blood&#xD;
           at day 8 of induction I&#xD;
&#xD;
        -  To validate new markers and methods for minimal residual disease (MRD) detection&#xD;
&#xD;
        -  To identify new prognostic factors by applying new technologies to study patient&#xD;
           material&#xD;
&#xD;
        -  To identify pharmacogenetic, pharmacokinetic and pharmacodynamic predictors for&#xD;
           treatment-related outcomes in the context of the systemic therapy used in the protocol&#xD;
&#xD;
        -  To describe the impact of antibiotic and antifungal prophylaxis on invasive bacterial&#xD;
           and fungal infections, febrile neutropenia, hospitalization, and antibiotic resistance.&#xD;
&#xD;
        -  To determine the performance characteristics of broad-range, molecular diagnostic&#xD;
           methods for detection of bacterial, fungal, and viral agents, in comparison to methods&#xD;
           currently in routine clinical use&#xD;
&#xD;
      Treatment will be based on cytogenetic and molecular characteristics, morphology, and&#xD;
      response to therapy as assessed by flow cytometry. Risk groups are defined below. The general&#xD;
      treatment plan will consist of chemotherapy for LR patients, chemotherapy ± NK cell therapy&#xD;
      for SR patients, and chemotherapy + stem cell transplant (SCT) for HR patients. HR patients&#xD;
      who do not have a suitable stem cell donor or who decline SCT will be eligible for NK cell&#xD;
      therapy.&#xD;
&#xD;
      Low-risk (LR) criteria (not eligible for SCT or NK cell therapy)&#xD;
&#xD;
        -  Core binding factor (CBF) leukemia [t(8;21)/AML1-ETO or inv(16)/t(16;16)/CBF-MYH11,] and&#xD;
           MRD &lt; 0.1% at day 22,regardless of other genetic features.&#xD;
&#xD;
        -  Patients with CBF leukemia who have MRD ≥ to 0.1% at day 22 or who have increasing&#xD;
           levels of fusion transcript will be considered SR and thus eligible for NK cell therapy.&#xD;
&#xD;
      Standard-risk (SR) criteria (eligible for NK cell therapy)&#xD;
&#xD;
        -  Absence of low-risk or high-risk features.&#xD;
&#xD;
        -  CBF leukemia with MRD ≥ 0.1% at day 22 or increasing levels of fusion transcript&#xD;
&#xD;
        -  FLT3-ITD and MRD &lt; 0.1% at day 22&#xD;
&#xD;
      High-risk (HR) criteria (candidates for SCT; eligible for NK cell therapy)&#xD;
&#xD;
      Presence of one of the following features:&#xD;
&#xD;
        -  t(6;9), t(8;16), t(16;21), -7, -5, or 5q-&#xD;
&#xD;
        -  FAB M0 or M6&#xD;
&#xD;
        -  FAB M7 without t(1;22)&#xD;
&#xD;
        -  Treatment-related (secondary) AML&#xD;
&#xD;
        -  RAEB-2 or AML arising from prior MDS&#xD;
&#xD;
        -  FLT3-ITD and MRD ≥ 0.1% at day 22&#xD;
&#xD;
        -  All other patients with poor response to therapy (must have one of the following&#xD;
           features) MRD ≥ to 5% at day 22 MRD ≥ to 0.1% after Induction II&#xD;
&#xD;
      Induction therapy (2 courses)&#xD;
&#xD;
      All patients will receive two courses of induction therapy that will include one course of&#xD;
      either high dose cytarabine, daunorubicin, and etoposide (HD-ADE) or one course of&#xD;
      clofarabine and cytarabine (Clo/AraC), followed by one course of low dose cytarabine,&#xD;
      daunorubicin, and etoposide (LD-ADE). Patients will be randomly assigned to receive one of&#xD;
      the following induction regimens.&#xD;
&#xD;
      Induction I: HD-ADE&#xD;
&#xD;
      Cytarabine: 3 g/m2 IV over 3 hours q12 hours x 6 doses (days 1, 3, 5) Daunorubicin: 50 mg/m2&#xD;
      (1.67 mg/kg for patients less than 10 kg) IV over 6 hours on days 2, 4, 6 (3 doses)&#xD;
      Etoposide: 100 mg/m2 IV over 4 hours on days 2-6 (5 doses)&#xD;
&#xD;
      Induction I: Clo/AraC&#xD;
&#xD;
      Clofarabine: 52 mg/m2 IV over 2 hours on days 1-5 (5 doses) Cytarabine: 1 gram/m2 IV over 2&#xD;
      hours on days 1-5 (5 doses; each dose to start 4 hours after the start of clofarabine)&#xD;
&#xD;
      Induction II: LD-ADE&#xD;
&#xD;
      Cytarabine: 100 mg/m2 IV over 30 minutes q12 hours on days 1-8 (16 doses), Daunorubicin: 50&#xD;
      mg/m2 (1.67 mg/kg for patients less than 10 kg) IV over 6 hours on days 2, 4, 6 (3 doses)&#xD;
      Etoposide: 100 mg/m2 IV over 4 hours on days 1-5 (5 doses)&#xD;
&#xD;
      Induction II for patients with FLT3-ITD: LD-ADE + Sorafenib&#xD;
&#xD;
      Patients with FLT3-ITD will take Sorafenib, 400 mg/m2 per day, orally in two divided doses&#xD;
      (200 mg/m2/dose BID) starting one day after the completion of Induction II and continuing for&#xD;
      21 days Patients with FLT3-ITD who do not experience toxicity related to Sorafenib will also&#xD;
      receive a 21-day course of Sorafenib after subsequent courses of chemotherapy.&#xD;
&#xD;
      Induction II for other HR patients: LD-ADE + vorinostat&#xD;
&#xD;
      [NOTE: Collaborating institutions may elect to opt out of treatment with vorinostat. If a&#xD;
      site opts out, then all applicable patients at that site will receive standard induction&#xD;
      therapy with LD-ADE (without vorinostat).]&#xD;
&#xD;
      Patients with M7 AML without t(1;22) and other HR patients without FLT3-ITD will be treated&#xD;
      with a combination of vorinostat and LD-ADE. Vorinostat will be given orally for 3 days (Days&#xD;
      -2, -1, 0) prior to the initiation of Induction II chemotherapy.&#xD;
&#xD;
      Special subgroup HR patients with MRD &lt; 0.1% may proceed directly to SCT after Induction I if&#xD;
      a suitable donor is available and the transplant can be performed without delay.&#xD;
&#xD;
      Consolidation I:&#xD;
&#xD;
      Mitoxantrone: 12 mg/m2 (0.4 mg/kg for patients less than 10 kg) IV over 1 hour on days 3-5 (3&#xD;
      doses) Cytarabine: 1 g/m2 IV over 2 hours every 12 hours on days 1-4 (8 doses)&#xD;
&#xD;
      Consolidation II:&#xD;
&#xD;
      Cytarabine 3 g/m2 IV over 3 hours every 12 hours on days 1, 2, 8, 9 (8 doses). Erwinia&#xD;
      Asparaginase 25,000 Units/m2 (833 Units/kg for infants &lt; 1 month of age, or for infants &lt; 3&#xD;
      months of age who were born significantly prematurely defined as &lt; 36 weeks gestation) IM or&#xD;
      IV over 1 hour, 3 hours after the 4th and 8th doses of cytarabine.&#xD;
&#xD;
      NK cell therapy Standard risk patients who have a KIR-mismatched family member who is greater&#xD;
      than 18 years old will undergo NK cell transplantation. In addition, HR patients who do not&#xD;
      have a suitable stem cell donor or who decline SCT will be eligible for NK cell therapy if&#xD;
      they have a KIR-mismatched family member.&#xD;
&#xD;
      Treatment schema Day -7: Cyclophosphamide 60 mg/kg IV over 1 hour. Mesna 15 mg/kg/dose IV&#xD;
      Days -6 through -2: Fludarabine 25 mg/m2/day IV over 30 minutes (5 doses) Days -1, +1, +3,&#xD;
      +5, +7, +9: IL-2 1 million units/m2 given subcutaneously Day -1: Donor pheresis Day 0: NK&#xD;
      cell infusion&#xD;
&#xD;
      No steroids, including the use of hydrocortisone as pre-medication, may be given to patients&#xD;
      during the 3 days prior to the NK cell infusion or during the first 7 days after the&#xD;
      infusion.&#xD;
&#xD;
      CNS therapy&#xD;
&#xD;
      Triple intrathecal therapy with methotrexate, hydrocortisone, and cytarabine (MHA) will be&#xD;
      used for all CNS therapy at the doses:&#xD;
&#xD;
      &lt; 1 year methotrexate 6 mg, hydrocortisone 12 mg, cytarabine 18 mg, 1-2 years methotrexate 8&#xD;
      mg, hydrocortisone 16 mg, cytarabine 24 mg, 2-3 years methotrexate 10 mg, hydrocortisone 20&#xD;
      mg, cytarabine 30 mg, &gt; 3 years methotrexate 12 mg, hydrocortisone 24 mg, cytarabine 36 mg&#xD;
&#xD;
      Leucovorin rescue (5 mg/m2 per dose; 5 mg maximum per dose) will be given orally or&#xD;
      intravenously at 24 and 30 hours after each IT MHA treatment.&#xD;
&#xD;
      Patients with no evidence of CNS disease \[(i.e., no leukemic blast cells on cerebrospinal&#xD;
      fluid (CSF) cytospin] will receive 4 total doses of intrathecal therapy, given at&#xD;
      approximately one month intervals or at the beginning of each of the first 4 courses of&#xD;
      chemotherapy.IT therapy will not be given before NK cell therapy.&#xD;
&#xD;
      Patients with overt CNS leukemia (less than or equal to 5 leukocytes per l of CSF and the&#xD;
      presence of leukemic blast cells on CSF cytospin) will receive weekly intrathecal therapy&#xD;
      until the CSF is free of blast cells (minimum number of doses, 4). These patients will then&#xD;
      receive 4 additional doses of intrathecal therapy (minimum total number of doses, 8) at&#xD;
      approximately 1-month intervals (generally given with each subsequent course of&#xD;
      chemotherapy).IT therapy will not be given before NK cell therapy.&#xD;
&#xD;
      Patients with &lt; 5 leukocytes per mul of CSF and the presence of leukemic blast cells on CSF&#xD;
      cytospin (CNS2)will receive weekly intrathecal therapy until the CSF is free of blast cells.&#xD;
      These patients will then receive 4 additional doses of intrathecal therapy at approximately&#xD;
      1-month intervals (generally given with each subsequent course of chemotherapy).IT therapy&#xD;
      will not be given before NK cell therapy.&#xD;
&#xD;
      Patients who are unable to undergo lumbar puncture and receive intrathecal therapy prior to&#xD;
      starting induction I should be treated as CNS2 unless they have overt CNS leukemia (CNS3).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2008</start_date>
  <completion_date type="Actual">August 14, 2020</completion_date>
  <primary_completion_date type="Actual">March 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 22 Minimal Residual Disease (MRD) Measured by Flow Cytometry</measure>
    <time_frame>Day 22 MRD measurement after one course of therapy</time_frame>
    <description>MRD-negative is defined as &lt;0.1% blasts with leukemia-associated phenotype detected by flow cytometry. MRD-positive is defined as &gt;=0.1% blasts with leukemia-associated phenotype detected by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.</measure>
    <time_frame>3 years after completion of therapy</time_frame>
    <description>Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.</measure>
    <time_frame>3 years after completion of therapy</time_frame>
    <description>Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>ADE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytarabine + Daunorubicin + Etoposide&#xD;
NK cells for infusion are prepared using the CliniMACS System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clo/AraC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clofarabine + Cytarabine&#xD;
NK cells for infusion are prepared using the CliniMACS System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>See Detailed Description</description>
    <arm_group_label>ADE</arm_group_label>
    <arm_group_label>Clo/AraC</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>See Detailed Description</description>
    <arm_group_label>ADE</arm_group_label>
    <other_name>Daunomycin</other_name>
    <other_name>Cerubidine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>See Detailed Description</description>
    <arm_group_label>ADE</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>Vepesid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>See Detailed Description</description>
    <arm_group_label>Clo/AraC</arm_group_label>
    <other_name>Clolar^TM</other_name>
    <other_name>Clofarex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS</intervention_name>
    <description>The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.</description>
    <arm_group_label>ADE</arm_group_label>
    <arm_group_label>Clo/AraC</arm_group_label>
    <other_name>Cell Selection System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age less than or equal to 21 years at time of study entry.&#xD;
&#xD;
          -  No prior therapy for this malignancy except for one dose of intrathecal therapy and&#xD;
             the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or&#xD;
             less ) for hyperleukocytosis.&#xD;
&#xD;
          -  Written informed consent according to institutional guidelines&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             within 2 weeks prior to enrollment&#xD;
&#xD;
          -  Male and female participants must use an effective contraceptive method during the&#xD;
             study and for a minimum of 6 months after study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Down syndrome&#xD;
&#xD;
          -  Acute Promyelocytic Leukemia (APL)&#xD;
&#xD;
          -  Juvenile Myelomonocytic Leukemia (JMML)&#xD;
&#xD;
          -  Fanconi anemia (FA)&#xD;
&#xD;
          -  Kostmann syndrome&#xD;
&#xD;
          -  Shwachman syndrome&#xD;
&#xD;
          -  Other bone marrow failure syndromes&#xD;
&#xD;
          -  Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as&#xD;
             specified in the protocol.&#xD;
&#xD;
          -  Use of investigational agents within 30 days or any anticancer therapy within 2 weeks&#xD;
             before study entry with the exception of IT therapy, hydroxyurea, or low-dose&#xD;
             cytarabine as stated above. The patient must have recovered from all acute toxicities&#xD;
             from any previous therapy.&#xD;
&#xD;
          -  Systemic fungal, bacterial, viral, or other infection not controlled (defined as&#xD;
             exhibiting ongoing signs/symptoms related to the infection and without improvement,&#xD;
             despite appropriate antibiotics or other treatment).&#xD;
&#xD;
          -  Pregnant or lactating patients.&#xD;
&#xD;
          -  Any significant concurrent disease, illness, or psychiatric disorder that would&#xD;
             compromise patient safety or compliance, interfere with consent, study participation,&#xD;
             follow up, or interpretation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Rubnitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute and Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook's Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Health System</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2008</study_first_posted>
  <results_first_submitted>March 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2018</results_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT00703820/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>324 participants enrolled between August 2008 and March 2017.</recruitment_details>
      <pre_assignment_details>Prior to starting the study, 62 participants were excluded for the following reasons: 29 participants were donors, 8 were determined to be ineligible (wrong diagnosis), 2 were MPAL (mixed AML) patients, and 23 were not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cytarabine+Daunorubicin+Etoposide</title>
          <description>Participants receive Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.</description>
        </group>
        <group group_id="P2">
          <title>Clofarabine+Cytarabine</title>
          <description>Participants receive Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk-adapted.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received non-protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cytarabine+Daunorubicin+Etoposide</title>
          <description>Participants receive Cytarabine + Daunorubicin + Etoposide as a first course followed by risk-adapted therapy.</description>
        </group>
        <group group_id="B2">
          <title>Clofarabine+Cytarabine</title>
          <description>Participants receive Clofarabine + Cytarabine as a first course followed by risk-adapted therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="129"/>
            <count group_id="B3" value="262"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.57" spread="6.00"/>
                    <measurement group_id="B2" value="9.05" spread="6.40"/>
                    <measurement group_id="B3" value="9.31" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Day 22 Minimal Residual Disease (MRD) Measured by Flow Cytometry</title>
        <description>MRD-negative is defined as &lt;0.1% blasts with leukemia-associated phenotype detected by flow cytometry. MRD-positive is defined as &gt;=0.1% blasts with leukemia-associated phenotype detected by flow cytometry.</description>
        <time_frame>Day 22 MRD measurement after one course of therapy</time_frame>
        <population>Of 262 randomized patients, 242 patients were included in day 22 MRD analysis. 20 patients were excluded due to: 16 were not evaluable by flow cytometry, 2 died prior to completing the first course of therapy, 2 were off therapy for unacceptable toxicity prior to completion of one course.</population>
        <group_list>
          <group group_id="O1">
            <title>Cytarabine+Daunorubicin+Etoposide</title>
            <description>Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.</description>
          </group>
          <group group_id="O2">
            <title>Clofarabine+Cytarabine</title>
            <description>Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk-adapted.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 22 Minimal Residual Disease (MRD) Measured by Flow Cytometry</title>
          <description>MRD-negative is defined as &lt;0.1% blasts with leukemia-associated phenotype detected by flow cytometry. MRD-positive is defined as &gt;=0.1% blasts with leukemia-associated phenotype detected by flow cytometry.</description>
          <population>Of 262 randomized patients, 242 patients were included in day 22 MRD analysis. 20 patients were excluded due to: 16 were not evaluable by flow cytometry, 2 died prior to completing the first course of therapy, 2 were off therapy for unacceptable toxicity prior to completion of one course.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MRD Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MRD Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was designed to test the null hypothesis that Cytarabine+Daunorubicin+Etoposide and Clofarabine+Cytarabine result in the same proportion of patients with positive MRD after 22 days. Power calculations indicate that enrollment of a total of 240 MRD-evaluable patients in a 5-stage Haybittle-Peto group sequential design gives 80% power at the 5% level to detect an odds ratio of 2.5. The design was developed using East statistical software.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The a priori threshold for statistical significance is 0.0429 so that the overall level of the study is maintained at 0.05 across the 4 interim analyses and the final analysis.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The p-value was computed using an exact, risk-group stratified, two-sided test.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
            <estimate_desc>The odds ratio is defined as the ratio of the odds that a Clofarabine+Cytarabine patient is MRD positive to the odds that a Cytarabine+Daunorubicin+Etoposide patient is MRD positive.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.</title>
        <description>Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment</description>
        <time_frame>3 years after completion of therapy</time_frame>
        <population>Randomized standard risk patients who received chemotherapy only</population>
        <group_list>
          <group group_id="O1">
            <title>Cytarabine+Daunorubicin+Etoposide</title>
            <description>Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.</description>
          </group>
          <group group_id="O2">
            <title>Clofarabine+Cytarabine</title>
            <description>Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk- adapted.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.</title>
          <description>Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment</description>
          <population>Randomized standard risk patients who received chemotherapy only</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="43.3" upper_limit="71.4"/>
                    <measurement group_id="O2" value="54.3" lower_limit="40.6" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.</title>
        <description>Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment</description>
        <time_frame>3 years after completion of therapy</time_frame>
        <population>Randomized patients who received NK cell therapy after chemotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Cytarabine+Daunorubicin+Etoposide</title>
            <description>Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.</description>
          </group>
          <group group_id="O2">
            <title>Clofarabine+Cytarabine</title>
            <description>Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk- adapted.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.</title>
          <description>Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment</description>
          <population>Randomized patients who received NK cell therapy after chemotherapy</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="31.0" upper_limit="99.7"/>
                    <measurement group_id="O2" value="77.8" lower_limit="54.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were monitored from the start of therapy through 30 days after this protocol's treatment plan was completed. Participants who received NK cell infusions were followed until any identified toxicities resolved to less than grade 2. Donors were followed for adverse events from the day of apheresis through seven days following apheresis.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cytarabine+Daunorubicin+Etoposide</title>
          <description>Participants received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.</description>
        </group>
        <group group_id="E2">
          <title>Clofarabine+Cytarabine</title>
          <description>Participants received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk-adapted.</description>
        </group>
        <group group_id="E3">
          <title>Stem Cell Donors</title>
          <description>This group enrolled in the study to provide donor cells to participants. Donors did not receive therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v. 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia (fever of unknown origin: not clinically or microbiologically documented)</sub_title>
                <description>ANC &lt;1.0x10e9/L, fever &gt;=38.5C</description>
                <counts group_id="E1" events="189" subjects_affected="90" subjects_at_risk="133"/>
                <counts group_id="E2" events="194" subjects_affected="95" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>DIC (disseminated intravascular coagulation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmia - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cardiac general - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia, sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction (cor pulmonale)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia, sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis, middle ear (non-infectious)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Ocular/visual - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Keratitis (corneal inflammation/corneal ulceration)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vision-photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Optic disc edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), oral cavity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Typhlitis (cecal inflammation)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, Anus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Sotmach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Enteritis (inflammation of the small bowel)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Lower GI NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic), oral cavity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, rectum</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Perforation, GI, appendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, dental/teeth/peridontal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, abdomen NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), small bowel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mucotitis/stomatitis (functional/symptomatic), esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Incontinence, anal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, lip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term, multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms - other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain - other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0x10e9/L)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/pancreas - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Allergy/immunology - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Allergic reaction to Asparaginase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically documented, ANC&lt;1.0x10e9/L, fever&gt;38.5C),blood</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="133"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbioogically) with Grade 3 or 4 neutrophils (ANC&lt;1.0x10e9/L)</sub_title>
                <counts group_id="E1" events="103" subjects_affected="71" subjects_at_risk="133"/>
                <counts group_id="E2" events="115" subjects_affected="77" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection - other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="133"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, blood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, lung (pneumonia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, catheter-related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, lip/perioral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intra-operative injury - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="47" subjects_affected="33" subjects_at_risk="133"/>
                <counts group_id="E2" events="62" subjects_affected="48" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="78" subjects_affected="45" subjects_at_risk="133"/>
                <counts group_id="E2" events="90" subjects_affected="48" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>AST, SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="133"/>
                <counts group_id="E2" events="35" subjects_affected="27" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Allbumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Alkalosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="133"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="133"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Potassium, serum-ghigh (hyperkalemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="133"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fibrinogen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, extremity-limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, buttock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, muscle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, joint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Growth and development - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, chest wall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy), extremity-upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, head/headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial, CN VI lateral deviation of eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>CNS necrosis/cystic progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neurology - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial, CN IX Motor-pharynx; sensory-ear, pharynx, tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration, anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mood alteration, depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Personality/behavioral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mood alteration, agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mood alteration, euphoria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Renal/genitourinary - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU, iuterus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory - other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, nose</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, bronchopulmonary NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hiccoughs (hiccups, singultus)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dermatology/skin - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain, skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/bleeding - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Acute vascular leak syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v. 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey E. Rubnitz, MD, PhD</name_or_title>
      <organization>St. Jude Children's Research Hospital</organization>
      <phone>901-595-2388</phone>
      <email>jeffrey.rubnitz@stjude.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

